"Is the Company blinded regarding the average event rates for each group regardless of being blinded on drug vs placebo ? Is it possible they are seeing a difference in the average event rates by statin type ? Could this signal confirmation of data seen in previous post hoc analyses ? I have no idea, merely posing a question."

Although all patients in BETonMACE are on atorvastatin (Lipitor) or rosuvastatin (Crestor), I don't think that there is any blinding as to which patient is taking which statin. However, they are blinded as to who is on apabetalone vs. placebo. So very doubtful in my opinion that too much can be inferred from looking at the blinded average event rate by statin type. I hope that apabetalone works with both atorvastatin and rosuvastatin to reduced MACE, and that the rosuvastatin/apabetalone combo works even better than the atorvastatin/apabetalon combo, consistent with the synergistic effect observed in the post-hoc of ASSURE.

BearDownAZ